Homa Mansoor
Overview
Explore the profile of Homa Mansoor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, Mansoor H, et al.
Clin Infect Dis
. 2025 Mar;
PMID: 40079698
Background: Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. The emergence of resistance to BDQ, a key drug in treating MDR-TB,...
2.
Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A, Galindo M, et al.
J Clin Tuberc Other Mycobact Dis
. 2024 Apr;
35:100433.
PMID: 38617837
Background: World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberculosis (DR-TB); however, data for patients with drug-resistant extrapulmonary tuberculosis (EPTB)...
3.
Das M, Mathur T, Ravi S, Meneguim A, Iyer A, Mansoor H, et al.
PLoS One
. 2024 Feb;
19(2):e0299482.
PMID: 38381772
[This corrects the article DOI: 10.1371/journal.pone.0248408.].
4.
Chavan V, Dalal A, Nagaraja S, Thekkur P, Mansoor H, Meneguim A, et al.
PLoS One
. 2024 Feb;
19(2):e0299477.
PMID: 38381762
[This corrects the article DOI: 10.1371/journal.pone.0234651.].
5.
Chiang S, Waterous P, Atieno V, Bernays S, Bondarenko Y, Cruz A, et al.
J Adolesc Health
. 2023 Feb;
72(3):323-331.
PMID: 36803849
No abstract available.
6.
Das M, Mathur T, Ravi S, Meneguim A, Iyer A, Mansoor H, et al.
PLoS One
. 2021 Mar;
16(3):e0248408.
PMID: 33690715
Background: Childhood multidrug-resistant TB (MDR-TB) still affects around 25000 children every year across the globe. Though the treatment success rates for drug-resistant TB (DR-TB) in children are better than adults,...
7.
Dhakulkar S, Das M, Sutar N, Oswal V, Shah D, Ravi S, et al.
PLoS One
. 2021 Feb;
16(2):e0246639.
PMID: 33600431
Background: Childhood and adolescent drug-resistant TB (DR-TB) is one of the neglected infectious diseases. Limited evidence exists around programmatic outcomes of children and adolescents receiving DR-TB treatment. The study aimed...
8.
Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F, Meneguim A, et al.
Clin Infect Dis
. 2020 Oct;
73(9):e3496-e3504.
PMID: 33079176
Background: The Médecins Sans Frontières Clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeutic...
9.
Chavan V, Dalal A, Nagaraja S, Thekkur P, Mansoor H, Meneguim A, et al.
PLoS One
. 2020 Jun;
15(6):e0234651.
PMID: 32544174
Background: Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is not possible. Though the...
10.
Paryani R, Gupta V, Singh P, Verma M, Sheikh S, Yadav R, et al.
Trop Med Infect Dis
. 2020 May;
5(2).
PMID: 32466438
While risk of tuberculosis (TB) is high among household contacts (HHCs) of pre-extensively drug resistant (pre-XDR) TB and XDR-TB, data on yield of systematic longitudinal screening are lacking. We aim...